UroToday8h
ASCO GU 2025: Prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial: Final Results
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a renal cell and testicular ...
UroToday23h
ASCO GU 2025: Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer – What’s Next
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...
UroToday23h
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: ‘EMBARK’ing on a Novel Treatment Paradigm
Historically, the recommended management for biochemically recurrent prostate cancer patients following maximal pelvic therapy with no metastasis on conventional imaging has been disease monitoring, ...
UroToday23h
APCCC Diagnostics 2025: What Do We Expect from Monitoring in Metastatic Prostate Cancer?
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Bertrand Tombal discussing what we can expect from ...